Anlon Healthcare IPO: Check IPO Date, Live Subscription and Key Details
Anlon Healthcare is a chemical manufacturing company engaged in the production of high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). These products are used as raw materials in various finished dosages like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. The company is one of the few domestic manufacturers of loxoprofen sodium dihydrate, a key ingredient for pain and inflammation treatment. It has 65 commercialized products, with a robust pipeline of 28 products at the pilot stage and 49 products under lab testing. Anlon has a manufacturing facility in Rajkot, Gujarat, which is equipped with an installed capacity of 400 MTPA and four in-house laboratories. The company has received Drug Master File (DMF) approvals from regulatory bodies in Brazil, China, and Japan, which enhances its export potential.
Key Metrics
Check Live GMP
Timeline
IPO Opens
26 Aug
IPO Closes
29 Aug
Allotment
1 Sept
Listing
3 Sept
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 26 August 2025 | Subscription starts |
| IPO Close Date | 29 August 2025 | Subscription ends |
| Allotment Date | 1 September 2025 | Allotment |
| Listing Date | 3 September 2025 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Retail (Min) | 1 | ₹14,924 |
Retail (Max)Just less than ₹2,00,000 | 13 | ₹1,94,012 |
SHNI (Min)Just above ₹2,00,000 | 14 | ₹2,08,936 |
SHNI (Max)Below ₹10,00,000 | 67 | ₹9,99,908 |
BHNIAbove ₹10,00,000 | 68 | ₹10,14,832 |
IPO Objectives
- Funding capital expenditure requirements for Proposed Expansion.
- Full or part repayment and/or prepayment of certain outstanding secured borrowings.
- Funding the working capital requirements of the Company.
- General corporate purposes.
Strengths
- The company has a strong product portfolio with 65 commercialized products and a scalable business model that includes a pipeline of new products under development.
- It benefits from high entry and exit barriers due to long customer approval cycles, which helps create strong customer loyalty and retention.
- The company has strong promoters and an experienced management team with deep industry expertise, providing strategic leadership.
- It has shown consistent financial growth, with revenue up 81% and profit after tax (PAT) rising by 112% between FY24 and FY25, indicating a strong financial turnaround.
- With a low debt-to-equity ratio of 0.73, the company has a much healthier balance sheet compared to previous years.
Weaknesses
- The company's revenue growth has been inconsistent, with a sharp decline in FY24, which raises concerns about business stability and its vulnerability to market disruptions.
- It has high customer concentration, as a small number of clients account for a significant portion of its revenue, making the company vulnerable to losing a major customer.
- The business operates with a single manufacturing facility in Rajkot, which could be a point of vulnerability to any localized disruptions.
- The company is working capital intensive, which is a concern for its cash flow, as a large portion of the IPO proceeds will be used for this purpose.
- It relies on a limited number of suppliers for raw materials, which exposes the company to potential supply chain risks and price volatility.
Financial Performance
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets (₹ Cr.) | 181.3 | 128 | 111.55 |
| Revenue (₹ Cr.) | 120.46 | 66.69 | 113.12 |
| PAT (₹ Cr.) | 20.52 | 9.66 | 5.82 |
| Net Worth (₹ Cr.) | 80.42 | 21.03 | 7.37 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Anlon Healthcare | 4.51 | 23.57 | 40.45% | 80.42 |
| Kronox Lab Sciences | 6.92 | 24.37 | 28.26% | 90.11 |
| Acutaas Chemicals | 8.85 | 61.3 | 12.15% | 683 |
Subscription Details
Daily Bids Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 0.91x | 1.01x | 1.07x |
| NII | 0.71x | 2.09x | 10.61x |
| S-HNI | 1.16x | 3.51x | 16.69x |
| B-HNI | 0.48x | 1.38x | 7.56x |
| RII | 8.99x | 22.33x | 47.26x |
| Total | 1.69x | 3.3x | 7.12x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 99,75,000 | 1,06,89,028 | 97.27 |
| NII | 19,95,000 | 2,11,61,412 | 192.57 |
| Small NII | 6,65,000 | 1,11,01,488 | 101.02 |
| Big NII | 13,30,000 | 1,00,59,924 | 91.55 |
| RII | 13,30,000 | 6,28,57,920 | 572.01 |
| Total | 1,33,00,000 | 9,47,08,360 | 861.85 |
Company Details
- Anlon Healthcare Ltd.
- 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat-360005
- +91 281 2562538
- cs@anloncro.com
- http://www.anlon.in/
Registrar Details
- Kfin Technologies Ltd.
- 04067162222, 04079611000
- ahl.ipo@kfintech.com
- https://ipostatus.kfintech.com/